SCYNEXIS Future Growth

Future criteria checks 5/6

SCYNEXIS is forecast to grow earnings and revenue by 48.7% and 30.8% per annum respectively while EPS is expected to grow by 49.2% per annum.

Key information

48.7%

Earnings growth rate

49.2%

EPS growth rate

Pharmaceuticals earnings growth23.9%
Revenue growth rate30.8%
Future return on equityn/a
Analyst coverage

Low

Last updated07 Nov 2024

Recent future growth updates

SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 12
SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Recent updates

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Aug 08
Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) 32% Price Drop

Jun 19
Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) 32% Price Drop

SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 12
SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

SCYNEXIS (NASDAQ:SCYX) Seems To Use Debt Rather Sparingly

Apr 04
SCYNEXIS (NASDAQ:SCYX) Seems To Use Debt Rather Sparingly

Scynexis: Update Following Restructuring Of GSK Deal

Apr 02

Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) Low P/S

Feb 01
Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) Low P/S

Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet?

Dec 21
Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet?

Little Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) Revenues As Shares Take 28% Pounding

Sep 26
Little Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) Revenues As Shares Take 28% Pounding

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Aug 17
Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Scynexis: Uninvestible At This Point, Downgrading To A Sell Rating

Aug 26

SCYNEXIS Q2 2022 Earnings Preview

Aug 12

FDA accepts Scynexis' application to expand label for vaginal yeast infections treatment

Aug 01

SCYNEXIS gains after favorable data for antifungal agent in new indication

Jul 19

SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially

Apr 07
SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially

SCYNEXIS, Inc.: Speculative Buy, Michael Burry Sold, But I Am Buying

Mar 07

Some Analysts Just Cut Their SCYNEXIS, Inc. (NASDAQ:SCYX) Estimates

Feb 13
Some Analysts Just Cut Their SCYNEXIS, Inc. (NASDAQ:SCYX) Estimates

Is SCYNEXIS (NASDAQ:SCYX) Using Debt In A Risky Way?

Dec 03
Is SCYNEXIS (NASDAQ:SCYX) Using Debt In A Risky Way?

Scynexis: Leading The Yeast Infection Treatment Industry

Jul 27

Scynexis' Brexafemme qualifies for 10 years of exclusivity for vaginal yeast infections

Jun 09

FDA approves SCYNEXIS' BREXAFEMME vaginal yeast infections treatment

Jun 02

Earnings and Revenue Growth Forecasts

NasdaqGM:SCYX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261116517404
12/31/2025538N/A124
12/31/202410-22N/A-144
9/30/20249-36-22-22N/A
6/30/202410-35-10-10N/A
3/31/20241401017575N/A
12/31/2023140676060N/A
9/30/2023136724545N/A
6/30/2023136441010N/A
3/31/20236-91-83-83N/A
12/31/20225-63-80-80N/A
9/30/20224-78-83-83N/A
6/30/20223-49-78-77N/A
3/31/20222-34-71-70N/A
12/31/202113-33-56-55N/A
9/30/202113-46-46-46N/A
6/30/202112-45-39-39N/A
3/31/202112-53-36-36N/A
12/31/2020N/A-55-49-49N/A
9/30/2020N/A-27-46-46N/A
6/30/2020N/A-36-47-47N/A
3/31/20200-38-46-46N/A
12/31/20190-54-38-38N/A
9/30/20190-37-31-31N/A
6/30/20190-29-27-26N/A
3/31/20190-31-27-27N/A
12/31/20180-12-29-28N/A
9/30/20180-22-28-27N/A
6/30/20180-31N/A-27N/A
3/31/20180-24N/A-26N/A
12/31/20170-25N/A-25N/A
9/30/20170-21N/A-24N/A
6/30/20170-24N/A-26N/A
3/31/20170-28N/A-27N/A
12/31/20160-30N/A-29N/A
9/30/20160-35N/A-31N/A
6/30/20160-31N/A-30N/A
3/31/20160-30N/A-29N/A
12/31/20150-28N/A-25N/A
9/30/20151-23N/A-20N/A
6/30/20151-19N/A-18N/A
3/31/20151-11N/A-14N/A
12/31/20141-7N/A-9N/A
9/30/20144-42N/A-9N/A
6/30/20148-43N/A-6N/A
3/31/201412-47N/A-2N/A
12/31/201317-47N/A-4N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SCYX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: SCYX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: SCYX is expected to become profitable in the next 3 years.

Revenue vs Market: SCYX's revenue (30.8% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: SCYX's revenue (30.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SCYX's Return on Equity is forecast to be high in 3 years time


Discover growth companies